USD 3.1205
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| CLOV | -0.9 | -4.3 | -9.0 | -13.1 | 155.8 | 225.1 | -23.0 | -69.4 | -69.4 | -69.4 |
| S&P 500 | -0.5 | -2.6 | -3.2 | 2.5 | 6.2 | 23.4 | 22.0 | 79.6 | 184.3 | 33035.4 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | CLOV |
| name | Clover Health Investments, Corp. |
| price | 3.1205 |
| changes percentage | -0.9352 |
| change | -0.0295 |
| day low | 3.105 |
| day high | 3.25 |
| year high | 4.71 |
| year low | 0.606 |
| market cap | 1563709904 |
| price avg 50 | 3.4848 |
| price avg 200 | 2.195395 |
| exchange | NASDAQ |
| volume | 2703360 |
| avg volume | 6792975 |
| open | 3.17 |
| previous close | 3.15 |
| eps | -0.19 |
| pe | -16.42 |
| earnings announcement | 2025-03-10T10:59:00.000+0000 |
| shares outstanding | 501108766 |
| timestamp | 2025-01-02 19:45:17 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001801170 | |||
| revenue | 2033720000 | 3476687000 | -41.50 |
| gross profit | 257332000 | 22735000 | 1031.88 |
| gross profit ratio | 0.13 | 0.01 | 1834.97 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 465874000 | 393659000 | 18.34 |
| interest income | 0 | 1363000 | -100.00 |
| interest expense | 7000 | 1363000 | -99.49 |
| ebitda | -210845000 | -337017000 | 37.44 |
| ebitdaratio | -0.1 | -0.11 | 2.51 |
| operating income | -208542000 | -370924000 | 43.78 |
| operating income ratio | -0.1 | -0.11 | 3.89 |
| net income | -213361000 | -305401000 | 30.14 |
| net income ratio | -0.1 | -0.09 | -19.43 |
| eps | -0.44 | -0.64 | 31.25 |
Revenue Growth: revenue decreased to 2,034 million in 2023 from 3,477 million in 2022 representing a change of -41.5%. This indicates a sales shrinking, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 466 million in 2023 from 394 million in 2022 representing a change of 18.34%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -211 million in 2023 from -337 million in 2022 representing a change of 37.44%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -209 million in 2023 from -371 million in 2022 representing a change of 43.78%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -213 million in 2023 from -305 million in 2022 representing a change of 30.14%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Gross Profit: Gross Profit increased to 257 million in 2023 from 23 million in 2022 representing a change of 1031.88%. This indicates a sales profitability growth, which is a positive sign for the company.
Earnings per Share (EPS): EPS increased to -0.44 in 2023 from -0.44 in 2022 representing a change of 31.25%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001801170 | |||
| revenue | 330986000 | 356243000 | -7.09 |
| gross profit | 275991000 | 107896000 | 155.79 |
| gross profit ratio | 0.83 | 0.3 | 175.31 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 284776000 | 100253000 | 184.06 |
| interest income | 0 | 0 | NaN |
| interest expense | 0 | 0 | NaN |
| ebitda | -8446000 | 7990000 | -205.71 |
| ebitdaratio | -0.03 | 0.02 | -213.77 |
| operating income | -8785000 | 7187000 | -222.23 |
| operating income ratio | -0.03 | 0.02 | -231.56 |
| net income | -9155000 | 7408000 | -223.58 |
| net income ratio | -0.03 | 0.02 | -233.01 |
| eps | -0.02 | 0.02 | -223.03 |
Revenue Growth: revenue decreased to 331 million in 2024Q3 from 356 million in 2024Q2 representing a change of -7.09%. This indicates a sales shrinking, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 285 million in 2024Q3 from 100 million in 2024Q2 representing a change of 184.06%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -8 million in 2024Q3 from 8 million in 2024Q2 representing a change of -205.71%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -9 million in 2024Q3 from 7 million in 2024Q2 representing a change of -222.23%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -9 million in 2024Q3 from 7 million in 2024Q2 representing a change of -223.58%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.02 in 2024Q3 from -0.02 in 2024Q2 representing a change of -223.03%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Gross Profit: Gross Profit increased to 276 million in 2024Q3 from 108 million in 2024Q2 representing a change of 155.79%. This indicates a sales profitability growth, which is a positive sign for the company.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001801170 | |||
| total assets | 570671000 | 808620000 | -29.43 |
| total liabilities | 284277000 | 460882000 | -38.32 |
| total equity | 286394000 | 347738000 | -17.64 |
| cash and cash equivalents | 122863000 | 103791000 | 18.38 |
| short term investments | 119822000 | 230970000 | -48.12 |
| long term investments | 119822000 | 138110000 | -13.24 |
| total current assets | 427970000 | 624997000 | -31.52 |
| total non current assets | 142701000 | 183623000 | -22.29 |
| total current liabilities | 261115000 | 440656000 | -40.74 |
| total non current liabilities | 23161999 | 20226000 | 14.52 |
| common stock | 49000 | 46000 | 6.52 |
| retained earnings | -2159794000 | -1955582000 | -10.44 |
| total debt | 4663000 | 5860000 | -20.43 |
Total Assets: Total Assets decreased to 571 million in 2023 from 809 million in 2022 representing a change of -29.43%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 286 million in 2023 from 348 million in 2022 representing a change of -17.64%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 120 million in 2023 from 231 million in 2022 representing a change of -48.12%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 428 million in 2023 from 625 million in 2022 representing a change of -31.52%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -2,160 million in 2023 from -1,956 million in 2022 representing a change of -10.44%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 284 million in 2023 from 461 million in 2022 representing a change of -38.32%. This indicates a decrease in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 123 million in 2023 from 104 million in 2022 representing a change of 18.38%. This indicates an increase in available liquid assets.
Total Current Liabilities: Total Current Liabilities decreased to 261 million in 2023 from 441 million in 2022 representing a change of -40.74%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 6.52%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 5 million in 2023 from 6 million in 2022 representing a change of -20.43%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001801170 | |||
| total assets | 653013000 | 674210000 | -3.14 |
| total liabilities | 310847000 | 349322000 | -11.01 |
| total equity | 342166000 | 324888000 | 5.32 |
| cash and cash equivalents | 287956000 | 254771000 | 13.03 |
| short term investments | 45096000 | 124281000 | -63.71 |
| long term investments | 198379000 | 103764000 | 91.18 |
| total current assets | 432727000 | 549576000 | -21.26 |
| total non current assets | 220286000 | 124634000 | 76.75 |
| total current liabilities | 279635000 | 324511000 | -13.83 |
| total non current liabilities | 31212000 | 24810999 | 25.80 |
| common stock | 50000 | 50000 | 0.00 |
| retained earnings | -2180711000 | -2171556000 | -0.42 |
| total debt | 3666000 | 4010000 | -8.58 |
Total Assets: Total Assets decreased to 653 million in 2024Q3 from 674 million in 2024Q2 representing a change of -3.14%. Suggesting a decrease in asset holdings.
Short Term Investments: Short Term Investments decreased to 45 million in 2024Q3 from 124 million in 2024Q2 representing a change of -63.71%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 433 million in 2024Q3 from 550 million in 2024Q2 representing a change of -21.26%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -2,181 million in 2024Q3 from -2,172 million in 2024Q2 representing a change of -0.42%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 311 million in 2024Q3 from 349 million in 2024Q2 representing a change of -11.01%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 342 million in 2024Q3 from 325 million in 2024Q2 representing a change of 5.32%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 288 million in 2024Q3 from 255 million in 2024Q2 representing a change of 13.03%. This indicates an increase in available liquid assets.
Total Current Liabilities: Total Current Liabilities decreased to 280 million in 2024Q3 from 325 million in 2024Q2 representing a change of -13.83%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 4 million in 2024Q3 from 4 million in 2024Q2 representing a change of -8.58%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001801170 | |||
| net change in cash | -9719000 | -113755000 | 91.46 |
| operating cash flow | -115871000 | -203926000 | 43.18 |
| free cash flow | -116455000 | -208393000 | 44.12 |
| capital expenditure | -584000 | -4467000 | 86.93 |
| depreciation and amortization | 2509000 | 1187000 | 111.37 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 140931000 | 164305000 | -14.23 |
| accounts payables | 4739000 | 7635000 | -37.93 |
| inventory | 0 | 8029000 | -100.00 |
| acquisitions net | 0 | -16200000 | 100.00 |
| investments in property plant and equipment | -584000 | -4467000 | 86.93 |
| net cash used for investing activites | 140013000 | 95133000 | 47.18 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 1150000 | 1400000 | -17.86 |
| common stock repurchased | -6220000 | -6362000 | 2.23 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -33861000 | -4962000 | -582.41 |
| cash at end of period | 176494000 | 186213000 | -5.22 |
| accounts receivables | 0 | -8029000 | 100.00 |
| cash at beginning of period | 186213000 | 299968000 | -37.92 |
Net Change in Cash: Net Change in Cash increased to -10 million in 2023 from -114 million in 2022 representing a change of 91.46%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -116 million in 2023 from -204 million in 2022 representing a change of 43.18%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -116 million in 2023 from -208 million in 2022 representing a change of 44.12%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 141 million in 2023 from 164 million in 2022 representing a change of -14.23%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 5 million in 2023 from 8 million in 2022 representing a change of -37.93%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to -1 million in 2023 from -4 million in 2022 representing a change of 86.93%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Receivables: Accounts Receivables increased to 0 in 2023 from -8 million in 2022 representing a change of 100.0%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001801170 | |||
| operating cash flow | 58847000 | 44757000 | 31.48 |
| free cash flow | 58448000 | 44360000 | 31.76 |
| capital expenditure | -399000 | -397000 | -0.50 |
| depreciation and amortization | 339000 | 330000 | 2.73 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 27988000 | 27900000 | 0.32 |
| accounts receivables | 68623000 | 33843000 | 102.77 |
| accounts payables | -14695000 | 5033000 | -391.97 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -399000 | -397000 | -0.50 |
| net cash used for investing activites | -12135000 | 4954000 | -344.95 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -23000 | 23000 | -200.00 |
| common stock repurchased | -4886000 | -3218000 | -51.83 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -4666000 | -3195000 | -46.04 |
| net change in cash | 33185000 | 46516000 | -28.66 |
| cash at end of period | 287956000 | 254771000 | 13.03 |
| cash at beginning of period | 254771000 | 208255000 | 22.34 |
Net Change in Cash: Net Change in Cash decreased to 33 million in 2024Q3 from 47 million in 2024Q2 representing a change of -28.66%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Stock-Based Compensation: Stock-Based Compensation increased to 28 million in 2024Q3 from 28 million in 2024Q2 representing a change of 0.32%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 15 million in 2024Q3 from 5 million in 2024Q2 representing a change of -391.97%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 69 in 2024Q3 from 34 million in 2024Q2 representing a change of 102.77%. This suggests that the company is less capable of collecting payments from its customers.
Operating Cash Flow: Operating Cash Flow increased to 59 million in 2024Q3 from 45 million in 2024Q2 representing a change of 31.48%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 58 million in 2024Q3 from 44 million in 2024Q2 representing a change of 31.76%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -0.5%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 4.22 | 7.3 | -42.22 |
| net income per share | -0.44 | -0.64 | 31.00 |
| operating cash flow per share | -0.24 | -0.43 | 43.88 |
| free cash flow per share | -0.24 | -0.44 | 44.81 |
| cash per share | 0.5 | 0.7 | -28.40 |
| book value per share | 0.59 | 0.73 | -18.65 |
| tangible book value per share | 0.59 | 0.69 | -14.59 |
| shareholders equity per share | 0.59 | 0.73 | -18.65 |
| interest debt per share | 0.0 | 0.01 | -99.87 |
| market cap | 459079890.52 | 442669041.53 | 3.71 |
| enterprise value | 340879890.52 | 344738041.53 | -1.12 |
| pe ratio | -2.15 | -1.45 | -48.44 |
| price to sales ratio | 0.23 | 0.13 | 77.29 |
| pocfratio | -3.96 | -2.17 | -82.52 |
| pfcf ratio | -3.94 | -2.12 | -85.58 |
| pb ratio | 1.6 | 1.27 | 25.92 |
| ptb ratio | 1.6 | 1.27 | 25.92 |
| ev to sales | 0.17 | 0.1 | 69.04 |
| enterprise value over ebitda | -1.62 | -1.02 | -58.05 |
| ev to operating cash flow | -2.94 | -1.69 | -74.02 |
| ev to free cash flow | -2.93 | -1.65 | -76.94 |
| earnings yield | -0.46 | -0.69 | 32.63 |
| free cash flow yield | -0.25 | -0.47 | 46.12 |
| debt to equity | 0 | 0.01 | -100.00 |
| debt to assets | 0 | 0.0 | -100.00 |
| net debt to ebitda | 0.56 | 0.29 | 92.92 |
| current ratio | 1.64 | 1.42 | 15.56 |
| interest coverage | -29791.71 | -272.14 | -10847.28 |
| income quality | 0.54 | 0.6 | -9.76 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.09 | 0.14 | -34.51 |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.01 | 0.02 | -78.82 |
| capex to operating cash flow | -0.01 | -0.02 | 76.99 |
| capex to revenue | 0.0 | 0.0 | -77.65 |
| capex to depreciation | 0.23 | 3.76 | -93.81 |
| stock based compensation to revenue | 0.07 | 0.05 | 46.63 |
| graham number | 2.43 | 3.25 | -25.08 |
| roic | -0.73 | -0.95 | 23.38 |
| return on tangible assets | -0.38 | -0.39 | 2.95 |
| graham net net | 0.09 | -0.14 | 164.84 |
| working capital | 166855000 | 184341000 | -9.49 |
| tangible asset value | 283404000 | 327738000 | -13.53 |
| net current asset value | 143693000 | 164115000 | -12.44 |
| invested capital | 178309000 | 214119000 | -16.72 |
| average receivables | 130495000 | 128287500 | 1.72 |
| average payables | 34814500 | 30287000 | 14.95 |
| average inventory | -50942000 | -127900500 | 60.17 |
| days sales outstanding | 20.43 | 15.45 | 32.24 |
| days payables outstanding | 7.64 | 3.43 | 122.84 |
| days of inventory on hand | 0 | -10.77 | 100.00 |
| receivables turnover | 17.87 | 23.63 | -24.38 |
| payables turnover | 47.77 | 106.46 | -55.12 |
| inventory turnover | 0 | -33.9 | 100.00 |
| roe | -0.74 | -0.88 | 15.17 |
| capex per share | 0.0 | 0.01 | -87.09 |
ROE: Return on Equity (ROE) increased to -0.74 on 2023-12-31 from -0.88 on 2022-12-31, representing a change of 15.17%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -2.15 on 2023-12-31 from -1.45 on 2022-12-31, representing a change of -48.44%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 1.64 on 2023-12-31 from 1.42 on 2022-12-31, representing a change of 15.56%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2023-12-31 from 0.01 on 2022-12-31, representing a change of -100.00%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| CLOV | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.68 | 0.73 | -7.60 |
| net income per share | -0.02 | 0.02 | -222.90 |
| operating cash flow per share | 0.12 | 0.09 | 30.76 |
| free cash flow per share | 0.12 | 0.09 | 31.03 |
| cash per share | 0.68 | 0.78 | -12.62 |
| book value per share | 0.7 | 0.67 | 4.74 |
| tangible book value per share | 0.69 | 0.66 | 4.79 |
| shareholders equity per share | 0.7 | 0.67 | 4.74 |
| interest debt per share | 0 | 0.0 | -100.00 |
| market cap | 1382307890.46 | 584979704.4 | 136.30 |
| enterprise value | 1098017890.46 | 334218704.4 | 228.53 |
| pe ratio | -37.75 | 19.74 | -291.21 |
| price to sales ratio | 4.18 | 1.64 | 154.33 |
| pocfratio | 23.49 | 13.07 | 79.72 |
| pfcf ratio | 23.65 | 13.19 | 79.34 |
| pb ratio | 4.04 | 1.8 | 124.37 |
| ptb ratio | 4.04 | 1.8 | 124.37 |
| ev to sales | 3.32 | 0.94 | 253.60 |
| enterprise value over ebitda | -130.0 | 41.83 | -410.80 |
| ev to operating cash flow | 18.66 | 7.47 | 149.87 |
| ev to free cash flow | 18.79 | 7.53 | 149.34 |
| earnings yield | -0.01 | 0.01 | -152.30 |
| free cash flow yield | 0.04 | 0.08 | -44.24 |
| debt to equity | 0 | 0.0 | -100.00 |
| debt to assets | 0 | 0.0 | -100.00 |
| net debt to ebitda | 33.66 | -31.38 | 207.25 |
| current ratio | 1.55 | 1.69 | -8.63 |
| interest coverage | 0 | 0 | NaN |
| income quality | -11.97 | 6.24 | -291.73 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.11 | 0.28 | -62.08 |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.0 | 0.0 | 3.25 |
| capex to operating cash flow | 0.01 | 0.01 | -23.56 |
| capex to revenue | 0.0 | 0.0 | 8.17 |
| capex to depreciation | 1.18 | 1.2 | -2.16 |
| stock based compensation to revenue | 0.08 | 0.08 | 7.97 |
| graham number | 0.54 | 0.48 | 13.46 |
| roic | -0.03 | 0.16 | -115.93 |
| return on tangible assets | -0.01 | 0.01 | -227.61 |
| graham net net | 0.16 | -0.47 | 133.25 |
| working capital | 153092000 | 225065000 | -31.98 |
| tangible asset value | 339176000 | 321898000 | 5.37 |
| net current asset value | 121880000 | 200254000 | -39.14 |
| invested capital | 164003000 | 236189000 | -30.56 |
| average receivables | 36619500 | 0 | NaN |
| average payables | 33093500 | 37924500 | -12.74 |
| average inventory | -260457000 | -520507500 | 49.96 |
| days sales outstanding | 19.91 | 0 | NaN |
| days payables outstanding | 42.13 | 14.66 | 187.49 |
| days of inventory on hand | 0 | -188.78 | 100.00 |
| receivables turnover | 4.52 | 0 | NaN |
| payables turnover | 2.14 | 6.14 | -65.22 |
| inventory turnover | 0 | -0.48 | 100.00 |
| roe | -0.03 | 0.02 | -217.34 |
| capex per share | 0.0 | 0.0 | -0.05 |
ROE: Return on Equity (ROE) decreased to -0.03 on 2024-09-30 Q3 from 0.02 on 2024-06-30 Q2, representing a change of -217.34%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -37.75 on 2024-09-30 Q3 from 19.74 on 2024-06-30 Q2, representing a change of -291.21%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 1.55 on 2024-09-30 Q3 from 1.69 on 2024-06-30 Q2, representing a change of -8.63%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2024-09-30 Q3 from 0.00 on 2024-06-30 Q2, representing a change of -100.00%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-12-23 11:56:10
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.
Sentiment: Positive
Publish Date: 2024-12-21 02:35:26
Clover Health's recent performance shows mixed results, with revenue growth but a significant share price drop, presenting a potential buying opportunity. Operational efficiency is improving, with better adjusted EBITDA and reduced net loss, indicating progress towards profitability. Wall Street remains optimistic, with positive ratings and a potential 46% upside, bolstered by a Medicare Advantage PPO plan upgrade.
Sentiment: Neutral
Publish Date: 2024-12-17 16:05:00
JERSEY CITY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Remote-First Company -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 4:30 p.m. Eastern Time.
Sentiment: Positive
Publish Date: 2024-12-11 07:19:27
Clover Health Investments shows financial progress and challenges in 2024, with a focus on innovative Medicare Advantage plans and technology-driven healthcare solutions. The company achieved a 4.0 rating for its PPO plan, indicating improved quality of care and potential for higher CMS reimbursements. Despite a slight membership decline, Clover's financial efficiency has improved, with net income losses decreasing significantly from 2022 to 2024.
Sentiment: Positive
Publish Date: 2024-12-05 10:55:16
After losing some value lately, a hammer chart pattern has been formed for Clover Health Investments (CLOV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Sentiment: Positive
Publish Date: 2024-12-04 09:01:30
Five medical info systems stocks have strong potential for 2025. These are: INSP, OMCL, TALK, BFLY, CLOV.
Sentiment: Positive
Publish Date: 2024-11-18 11:50:17
Clover's 32% dip following its Q3 earnings could be an opportunity to accumulate shares. Clover continues to grow its topline and improve its bottom line performance. Clover's latest star rating upgrade to 4 stars for payment year 2026 could help it increase its market share and secure more deals for Counterpart Assistant.
Sentiment: Positive
Publish Date: 2024-11-15 10:36:12
Clover Health Investments (CLOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Sentiment: Positive
Publish Date: 2024-11-14 10:35:19
The heavy selling pressure might have exhausted for Clover Health Investments (CLOV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Sentiment: Neutral
Publish Date: 2024-11-12 10:56:10
After losing some value lately, a hammer chart pattern has been formed for Clover Health Investments (CLOV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Sentiment: Positive
Publish Date: 2024-11-07 12:20:19
Clover Health's third-quarter 2024 results continue to benefit from the strength of its business model.
Sentiment: Negative
Publish Date: 2024-11-06 19:26:30
Clover Health Investments, Corp. (CLOV) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
Sentiment: Positive
Publish Date: 2024-11-06 18:50:38
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Ryan Schmidt - Investor Relations Andrew Toy - Chief Executive Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong - UBS John French - Leerink Partners Operator Ladies and gentlemen, good afternoon. And welcome to the Clover Health Third Quarter 2024 Earnings Conference Call.
Sentiment: Positive
Publish Date: 2024-11-06 03:41:55
Clover Health's pivot to profitability over growth following the divestiture of the non-insurance segment at the end of 2023 has led to significant earnings improvements. The newly launched Counterpart Health platform could diversify the company's revenue, offsetting risks from declining Medicare Advantage memberships. The company has a strong balance sheet with no long-term debt and high liquidity ratios.
Sentiment: Positive
Publish Date: 2024-11-04 13:46:22
The continued strength in Clover Health's offerings is likely to have driven the company's performance in the third quarter.
Sentiment: Neutral
Publish Date: 2024-10-23 16:05:00
FRANKLIN, Tenn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), today announced that it will report third quarter 2024 financial results after market close on Wednesday, November 6, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on November 6, 2024, to discuss Clover Health's third quarter 2024 business and financial results.
Sentiment: Positive
Publish Date: 2024-10-15 09:15:00
Company's affordable, benefit-rich flagship PPO plans now have 4 Star rating Company's affordable, benefit-rich flagship PPO plans now have 4 Star rating
Sentiment: Positive
Publish Date: 2024-10-10 17:03:00
Overall Star rating performance increase was driven by exceptional performance on healthcare quality measures, Medication Adherence and Member Experience Overall Star rating performance increase was driven by exceptional performance on healthcare quality measures, Medication Adherence and Member Experience
Sentiment: Positive
Publish Date: 2024-10-08 06:15:00
Dr. Tsay Brings Unique Expertise in AI, Digital Health, and Clinical Innovation to Counterpart Health Dr. Tsay Brings Unique Expertise in AI, Digital Health, and Clinical Innovation to Counterpart Health
Sentiment: Positive
Publish Date: 2024-10-06 13:16:26
Chamath Palihapitiya is a prominent venture capitalist, engineer, and entrepreneur known for his significant contributions to the tech sector.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
